University of Kentucky awarded $6 million for GDNF and related research
12th Sep 2005, 23:04 GMT
The University of Kentucky Morris K. Udall Parkinson's Disease Research Center of Excellence has been awarded nearly $6 million from National Institutes of Health and National Institute of Neurological Disorders and Stroke to continue work on the promising drug glial cell line-derived neurotrophic factor (GDNF) and similar compounds. Human trials of GDNF recently ended in legal controversy when drug manufacturer Amgen, Inc., revoked trial sponsorship from investigators and treatment from patients.
Latest news from EurekAlert! - Policy and Ethics:
- Bariatric surgery complication rates high in some hospitals, new HealthGrades ratings and study show
- A company's reputation is what gets fried when its books get cooked
- Sensor networks protect containers, navigate robots
- Queen's Surveillance Project benchmarks global attitudes about being watched
- Elderly, ill men get unneeded prostate cancer screenings
- Want fair and affordable health insurance for the uninsured? Ask the public to design it
- New book by University of Minnesota historian exposes Turkey's responsibility in Armenian genocide
- The Last Great Wilderness
- 'Moral clarity' espoused in debate over health-care reform
- RAND study says US should greatly expand efforts